Spruce Biosciences Analyst Ratings
Spruce Biosciences Analyst Ratings
Hold Rating on Spruce Biosciences Amid Clinical Trial Uncertainties and Rising Competition
Buy Rating Affirmed for Spruce Biosciences Amid Upcoming Trial Data and Strong Financial Position
Spruce Biosciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Spruce Biosciences (SPRB)
Spruce Biosciences Analyst Ratings
Analysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)
Buy Rating Affirmed for Spruce Biosciences Amid Clinical Trial Optimism and Advancing Dose Cohorts
Spruce Biosciences Analyst Ratings
RBC Capital Reiterates Outperform on Spruce Biosciences, Maintains $9 Price Target
Spruce Biosciences Analyst Ratings
RBC Lifts Price Target on Spruce Biosciences to $9 From $8, Cites Improved Chances of Congenital Adrenal Hyperplasia Program Success; Outperform, Speculative Risk Kept
Spruce Biosciences (SPRB) Gets a Buy From RBC Capital
Spruce Biosciences Analyst Ratings
Buy Rating on Spruce Biosciences: Anticipating Success With Tildacerfont Amid a $2 Billion Market Opportunity
Analysts Offer Insights on Healthcare Companies: Spruce Biosciences (SPRB) and Inhibrx (INBX)
Analysts Are Bullish on These Healthcare Stocks: Enanta Pharmaceuticals (ENTA), Spruce Biosciences (SPRB)
Buy Rating Affirmed for Spruce Biosciences Amid Positive Clinical Trials and Market Potential for Tildacerfont
Analysts Are Bullish on Top Healthcare Stocks: Collegium Pharmaceutical (COLL), Spruce Biosciences (SPRB)